Shares of Bristol-Myers Squibb Co (NYSE:BMY) ended Monday session in green amid volatile trading. The shares closed up +0.74 points or 1.37% at $54.66 with 9.70 million shares getting traded. Post opening the session at $53.94, the shares hit an intraday low of $53.56 and an intraday high of $54.70 and the price vacillated in this range throughout the day. The company has a market cap of $91.41 billion and the numbers of outstanding shares have been calculated to be 1.66 billion shares.
Bristol-Myers Squibb Co (BMY) announced new data across eight tumor types evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), as monotherapy or in combination, as well as new assets, to be presented at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark from October 7–11. Data presented at this congress underscore the Company’s commitment to its portfolio and to discover the next wave of transformational Immuno-Oncology medicines, including combination therapies, for difficult-to-treat cancers.
“Bristol-Myers Squibb continues to lead the scientific understanding of Immuno-Oncology with an extensive portfolio and a differentiated clinical development program where we have set a high bar of success to look for clear and differentiated improvements over currently available therapies,” said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. “We remain focused on expanding the use of the Opdivo and Yervoy combination to more tumors, and bringing forward novel agents and combination regimens in earlier lines of therapy, to help even more patients with cancer.”
Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Monday session in green amid volatile trading. The shares closed up +0.64 points or 3.53% at $18.77 with 2.23 million shares getting traded. Post opening the session at $18.12, the shares hit an intraday low of $17.85 and an intraday high of $18.80 and the price vacillated in this range throughout the day. The company has a market cap of $2.92 billion and the numbers of outstanding shares have been calculated to be 160.90 million shares.
Horizon Pharma PLC (HZNP) announced that it has entered into a rebate agreement with Prime Therapeutics, which secures formulary status for its primary care medicines. The rebate agreement begins on October 1, 2016.
“Our philosophy is and will continue to be to ensure that patients have access to the medicines their physicians prescribe,” said Timothy P. Walbert, chairman, president and chief executive officer. “The Prime Therapeutics rebate agreement in addition to the previously announced CVS/Caremark agreement provides increased access to patients as well as sustainability and durability for our primary care business. We continue discussions and negotiations with other pharmacy benefit managers and payers with the goal of further increasing patient access for our clinically relevant primary care medicines.”